UF-KURE-BCMA CAR-T Cells

A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE-BCMA CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
12 patients (estimated)
Sponsors
Case Comprehensive Cancer Center
Tags
CAR T Cell, B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
2039
NCT Identifier
NCT06698744

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.